



Published in final edited form as:

Biochemistry. 2012 April 3; 51(13): 2775–2784. doi:10.1021/bi2017987.

A highly conserved interaction involving the middle residue of the SXN active-site motif is crucial for function of Class B penicillin-binding proteins: mutational and computational analysis of PBP 2 from *N. gonorrhoeae*

Joshua Tomberg[‡], Brenda Temple^{§,¶}, Alena Fedarovich[†], Christopher Davies[†], and Robert A. Nicholas^{*,‡}

[‡]Department of Pharmacology University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365

[§]Departments of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365

[¶]Departments of R. L. Juliano Structural Bioinformatics Core Facility, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365

[†]Department of Biochemistry, Medical University of South Carolina, Charleston, South Carolina 29425

Abstract

Insertion of an aspartate residue at position 345a in penicillin-binding protein 2 (PBP 2), which lowers the rate of penicillin acylation by ~6-fold, is commonly observed in penicillin-resistant strains of *Neisseria gonorrhoeae*. Here, we show that insertions of other amino acids also lower the penicillin acylation rate of PBP 2, but none supported growth of *N. gonorrhoeae*, indicating loss of essential transpeptidase activity. The Asp345a mutation likely acts by altering the interaction between its adjacent residue, Asp346, in the β 2a- β 2d hairpin loop and Ser363, the middle residue of the SXN active site motif. Because the adjacent aspartate creates ambiguity in the position of the insertion, we also examined if insertions at position 346a could confer decreased susceptibility to penicillin. However, only aspartate insertions were identified, indicating that only an Asp-Asp couple can confer resistance and retain transpeptidase function. The importance of the Asp346-Ser363 interaction was assessed by mutation of each residue to Ala. Although both mutants lowered the acylation rate of penicillin G by 5-fold, neither could support growth of *N. gonorrhoeae*, again indicating loss of transpeptidase function. Interaction between a residue in the equivalent of the β 2a- β 2d hairpin loop and the middle residue of the SXN motif is observed in crystal structures of other Class B PBPs and its importance is also supported by multi-sequence alignments. Overall, these results suggest that this conserved interaction can be manipulated (e.g. by insertion) to lower the acylation rate by β -lactam antibiotics and increase resistance, but only if essential transpeptidase activity is preserved.

*Corresponding author: Tel. (919) 966-6547. nicholas@med.unc.edu.

Supplemental Information Available

Supplemental materials may be accessed free of charge online at <http://pubs.acs.org>. Fig. 1S: Superimposition of NgPBP 2 and SpPBP 2x in the region around the SXN active-site motif; Fig 2S: Multi-sequence alignment of Group 1 (SSN motif) PBPs; Fig. 3S: Multi-sequence alignment of Group 2 (SCN motif) PBPs; and Fig. 4S: Multi-sequence alignment of Group 3 (SDN motif) PBPs.

Keywords

penicillin-binding protein; *Neisseria gonorrhoeae*; antibiotic resistance; multiple sequence alignment

Introduction

Neisseria gonorrhoeae is an obligate human pathogen that is the etiologic agent of the sexually transmitted infection gonorrhea. In 2007, over 350,000 infections were reported in the U.S. (1), but the actual number may be twice that. Gonococcal infections in females are often asymptomatic and, if left untreated, can progress to pelvic inflammatory disease. There is a risk of disseminated infections in both sexes, and individuals infected with *N. gonorrhoeae* have an increased likelihood of both transmitting and acquiring HIV (2, 3). Because of the lack of a robust immune response or an effective vaccine, antibiotics are the mainstay for treating gonococcal infections.

Historically, *N. gonorrhoeae* has become resistant to nearly all antibiotics that have been used to treat infections, including penicillin, tetracycline, azithromycin, and fluoroquinolones, leaving the expanded-spectrum cephalosporins, ceftriaxone and cefixime, as the only antibiotics currently recommended by the Centers for Disease Control (CDC). Unfortunately, the emergence of strains over the past decade with decreased susceptibility to these antibiotics (4), together with the recent isolation of gonococcal strains from Japan (5, 6) and France (7) with confirmed MICs for ceftriaxone of 2 $\mu\text{g/ml}$ (>10-fold higher than previous isolates), suggests that the continued effectiveness of these antibiotics is uncertain. The marked decrease in susceptibility to the expanded-spectrum cephalosporins makes it imperative that we understand the molecular mechanisms that lead to resistance and that new antibiotics be developed.

Chromosomally mediated resistance to penicillin and expanded-spectrum cephalosporins is complex and multi-faceted. Resistance arises following acquisition of multiple mutant alleles of endogenous genes/loci that work together to increase resistance to the antibiotic (8). *N. gonorrhoeae* is naturally competent, and thus resistance determinants can be transferred from a resistant isolate to a susceptible strain in a step-wise manner by DNA uptake and homologous recombination (9, 10). The first step is acquisition of an altered *penA* allele encoding penicillin-binding protein 2 (PBP 2), the lethal target for penicillin in the gonococcus. These altered forms, particularly in strains with decreased susceptibility to cephalosporins, have evolved by interspecies recombination with closely related pathogenic and commensal *Neisseria* species, including *N. meningitidis*, *N. flavescens*, *N. cinerea*, and *N. lactamica* (11). A single altered *penA* allele can arise from multiple recombination events and accumulate >60 mutations. A major goal is to understand how these changes affect β -lactam binding and acylation of PBP 2.

All bacteria are surrounded by peptidoglycan, which confers rigidity and viability to the cell. Peptidoglycan is composed of glycan strands of a repeating disaccharide, N-acetylglucosamine- β -1,4-N-acetylmuramic acid, in which every muramic acid residue is substituted with a peptide chain (12, 13). PBPs catalyze the cross-linking of the peptide chains during the final steps of peptidoglycan synthesis. A serine nucleophile from the PBP attacks the penultimate *D*-Ala residue of the *D*-Ala-*D*-Ala carboxy terminus of the peptide chain, forming an acyl-enzyme bond that is subsequently attacked by an amino group from another peptide chain, forming a cross-link between two glycan strands (transpeptidation). β -lactam antibiotics, by virtue of their similarity to acyl-*D*-Ala-*D*-Ala, react with PBPs to form stable acyl-enzyme complexes that effectively inhibit activity (14).

PBPs are generally classified either as high-molecular-mass (HMM) PBPs, which catalyze transpeptidation of peptide chains and are essential for cell viability, or low-molecular-mass (LMM) PBPs, which catalyze carboxypeptidase or endopeptidase activity and are not essential for cell viability (15). HMM PBPs are divided into two classes: Class A PBPs catalyze both a penicillin-insensitive transglycosylase (TGase) activity and penicillin-sensitive transpeptidase (TPase) activity, whereas Class B PBPs catalyze only TPase activity. Further subdivision of each of these classes into A1 to A7 and B1 to B6 + B-like I to B-like III has been proposed based on structural and homology considerations (16, 17). All PBPs contain three conserved sequence motifs that form the catalytic center of the active site: the SxxK tetrad, which contains the serine nucleophile that reacts with peptides and β -lactams, the SXN triad, and the KTG triad. While these conserved motifs are mostly invariant, substitutions nearby or in other regions surrounding the active site collaborate to decrease the acylation rate with β -lactam antibiotics without compromising transpeptidase activity (18-22).

PBP 2 variants from penicillin-resistant (but cephalosporin-susceptible) strains of *N. gonorrhoeae*, a Class B PBP, commonly contain both an Asp insertion after Arg345 (termed Asp345a) in the β 2a- β 2d hairpin loop adjacent to the active site and 4 to 8 mutations in the C-terminus (23). We recently solved the crystal structure of PBP 2 from a penicillin-susceptible strain of *N. gonorrhoeae* and a PBP 2 variant from a penicillin-resistance strain containing 4 C-terminal amino acid substitutions (20). These structures shed light on the mechanisms by which these C-terminal mutations decrease the rate of acylation of the PBP 2 by β -lactam antibiotics, but unfortunately no constructs harboring the Asp345a insertion crystallized, and thus the structural mechanism by which this insertion lowers the rate of acylation remains unclear.

In this study, we investigated the mechanism by which Asp345a insertions alter the acylation rate of penicillin for PBP 2. We focused on the interaction of Asp346 (the amino acid adjacent to Asp345a) with Ser363 (the X in the SXN motif), which is the most likely interaction affected by Asp345a (20). We show that this interaction is essential for TPase function (but not β -lactam-binding), and further, that all Class B PBPs have a conserved interaction between the middle residue of the SXN motif and a residue in the loop that precedes the motif.

Materials and Methods

Strains and plasmids

FA19 is a penicillin- and cephalosporin-susceptible wild type strain that served as the recipient strain for all of the transformation experiments (24). FA19 was grown on GC Broth (GCB) agar plates containing supplements I and II (25) in a 4% CO₂/96% air atmosphere at 37°C. In most cases, the wild-type *penA* gene from FA19 was used as the template for mutations and 345a/346a insertions, but in some cases i.e., those where the mutations or insertions did not decrease the k_2/K_S acylation rate constant more than threefold, the *penA35* gene from strain 35/02 (a cephalosporin intermediate-resistant or Ceph^I strain; (26)) was used as template (see below). For transformation experiments, the *penA* genes being transformed were either cloned into pUC18us, which is pUC18 containing a 10-bp gonococcal uptake sequence (27), or were constructed by PCR and transformed directly into FA19. In the latter case, one of the primers for PCR amplification contained the uptake sequence appended to its 5' end. The plasmid for overexpression and purification of PBP 2 constructs (a derivative of pMAL-C2; New England Biolabs, Beverly, MA) was described in earlier publications (20, 28). *E. coli* strain MC1061 was used for routine subcloning, while GW6011 (MC4100 *lon-146::Tn10*) was used for protein purification.

Mutagenesis

Mutations and insertions were incorporated into the *penA* or *penA35* gene by overlap-extension PCR (29). The templates for the reactions were pUC18us-*penA* or pUC18us-*penA35* (21). For the 346a insertion library, the 3' internal gene-specific primer was complementary to the *penA* sequence from codons 340-346, contained three random bases, and then had complementary sequence from codons 347-353, while the 5' internal primer consisted of codons 347-353. Following amplification of the two halves of the *penA* gene, the individual amplification products were purified, mixed back together, and amplified with only the outside vector-specific primers. The assembled large fragment was digested and cloned back into pUC18us, the ligation was transformed into MC1061, and the library of plasmid clones was purified. Sequencing of the library confirmed the presence of all four bases in essentially equal amounts at the 3 positions of codon 346a.

Assessment of TPase activity of PBP 2 mutants by transformation

There is no *in vitro* assay capable of quantifying TPase activity of Class B PBPs, as these PBPs do not react with model substrates or cross-link linear peptidoglycan. However, since PBP 2 is essential for the growth and viability of *N. gonorrhoeae* (23, 30), we assessed TPase function of the PBP 2 mutants by determining whether they were capable of transforming *N. gonorrhoeae*. Previous experiments showed that resistant colonies could be readily selected when FA19 was transformed with *penA* DNA encoding PBP 2 mutants with threefold decrease in the acylation rate constant and plated at penicillin concentrations just above its minimal inhibitory concentration (MIC) (see below) (20). Anything below this threshold was difficult to select without obtaining significant numbers of untransformed colonies.

For those mutations that did not decrease the k_2/K_S of penicillin G below threefold, we incorporated the mutations into PBP 235/02, which confers a 100-fold increase in the MIC of cefixime when expressed in FA19 (31). While it is possible that the 345a/346a insertions might affect activity of PBP 2^{35/02} differently than wild-type PBP 2 (due to the presence of 58 amino acid changes), PBP 2^{35/02}-D345a was functional and capable of transforming FA19, and thus there appear to be no negative interactions between the insertion and the other alterations in PBP 2^{35/02}.

Transformation of *penA* mutant constructs into FA19 was accomplished as described previously (32). Transformants were selected on GCB plates containing 0.02 μg/ml penicillin G, which is 2-fold higher than its MIC (32). To verify correct recombination, transformants were passaged on GCB plates, colonies were boiled in 25 μl water, spun briefly to pellet cell debris, and the supernatants were used as templates in PCR reactions with the appropriate *penA* primers. PCR products were sequenced by the UNC sequencing facility or by Eton Bioscience Inc. (Research Triangle Park, NC). Transformations of mutants in the *penA35* allele from strain 35/02 were plated on GCB plates containing 0.01 μg/ml cefixime (~3-fold higher than its MIC) (21, 31).

Purification of PBP 2 variants

PBP 2 variants were purified as described previously (20). Briefly, the genes encoding each variant were cloned into a derivative of pMAL-C2 (New England Biolabs, Beverly, MA), pMAL-C2KV, which fuses His₆-maltose-binding protein and an intervening tobacco etch virus (TEV) protease site to amino acid 44 of PBP 2, and the proteins were expressed in *E. coli* (this construct removes the N-terminal transmembrane anchor and greatly increases the expression levels and solubility of the PBP). The fusion proteins were purified on a Ni²⁺-NTA column (GE Healthcare, Piscataway, NJ), cleaved with His6-tagged TEV protease, and the digests were re-chromatographed over a Ni²⁺-NTA column. The purified proteins were

eluted in TNG buffer (20 mM Tris, 500 mM NaCl, 10% glycerol, pH 8.0) containing 15 mM imidazole, while uncleaved protein, His6-TEV and His6-maltose-binding protein were eluted with TNG buffer containing 250 mM imidazole. The proteins were dialyzed in TNG buffer to remove imidazole, concentrated to ~ 6 mg/ml, and frozen at -80°C .

k_2/K_S measurements of the rate of acylation by β -lactam antibiotics

The reaction of β -lactam antibiotics with PBP 2 is denoted by the following equation:

$E+S \xrightleftharpoons{K_S} E \bullet S \xrightarrow{k_2} E-S' \xrightarrow{k_3} E+P$, where $E \bullet S$ is the non-covalent enzyme-antibiotic complex, $E-S'$ is the acyl-enzyme complex, and P the hydrolyzed antibiotic. k_2/K_S constants, which are a direct measure of the ability of an antibiotic to inhibit a PBP (33), were calculated from first order rates of acylation of purified, soluble PBP 2 variants by [^{14}C]penicillin G (Moravsek, Brea, CA), as previously described (20, 34). Graphs of PBP 2- [^{14}C]penicillin G complex formation versus time were obtained by incubating 27 μg of protein with 0.5-1.0 μM [^{14}C]penicillin G, and aliquots of ~4 μg were removed at 15 sec intervals, precipitated with 5% trichloroacetic acid, filtered over Whatman GC-A filters, and the filters were submitted to scintillation counting.

Bioinformatics

A Blast search using *N. gonorrhoeae* PBP 2 as a query was carried out using the Swiss Institute for Bioinformatics Blast program (35) at www.expasy.org. The top 1000 sequences were selected and those with >90% similarity were culled by the Blast program. Because there were far fewer sequences with SDN and SCN motifs than SSN motifs in the original search, the Blast search and culling was repeated using either PBP 2a from *S. aureus* (SDN motif) or PBPA from *M. tuberculosis* (SCN motif) as the query sequence. The three groups of sequences were then aligned separately using the multi-sequence alignment program, MUSCLE (36). The region comprising the equivalent of the β 2a- β 2d hairpin extension loop through the SXN motif of the different alignments was extracted and used to create Sequence Logos (37) through the web based application, WebLogo (38) (weblogo.berkeley.edu).

Proteolytic sensitivity of PBP 2 variants

Purified PBPs (100 μg) were diluted to 56 μl with TNG buffer, and 10 μl was removed and added to 2.5 μl of 5X SDS-PAGE sample buffer (0 time point). Trypsin (1 μl of a 50 ng/ μl solution) was added to the remainder of the protein at room temperature, and 10 μl of the digest was removed at 5, 10, 30, and 60 min and denatured as above. The samples were heated at 95°C for 5 min after denaturation, and 10 μl of each sample was separated on a 10% SDS-polyacrylamide gel. The proteins were stained with Coomassie Brilliant Blue R-250 and the gel was scanned on a Typhoon 9400 Variable Mode Imager (GE Healthcare, Piscataway, NJ) using the red 633 nm laser for fluorescence excitation.

Results

Random 346a codon insertions

As shown by the crystal structure of PBP 2 (20), the Asp345a insertion is located after Arg345 on the β 2a- β 2d loop that lies above the active site in close proximity to the SXN active-site motif (Fig. 1A). The residue following the insertion site, Asp346, is involved in an intimate hydrogen-bonding network in which the carboxylate of Asp346 contacts Ser363 (the X in the SXN motif) and two amide nitrogens at the N-terminal end of the α 5 helix (Fig. 1B), and we have hypothesized that the aspartate insertion exerts its effect by altering this interaction (20). One of the curious aspects of the Asp345a insertion in PBP 2 is that aspartate is the only amino acid observed in clinical isolates, and selection of transformants

of a laboratory strain with a library of *penA* genes containing random codon insertions at position 345a revealed only aspartate codon insertions, leading to the conclusion that aspartate is the only amino acid insertion capable of decreasing susceptibility to penicillin (39). However, because position 346 is also an aspartate, the assignment of the insertion position is ambiguous, *i.e.* it could be Asp345a or Asp346a.

To investigate whether amino acid insertions (other than aspartate) at position 346a are capable of decreasing susceptibility to penicillin, we constructed a library of *penA* genes containing a randomized codon insertion at position 346a and used this to transform FA19 (a penicillin-susceptible wild-type strain of *N. gonorrhoeae*), selecting for transformants with decreased susceptibility to penicillin G. The *penA* genes from fifteen transformants were amplified and sequenced, but in each instance, only an aspartate codon (either GAC or GAT) at position 346a was recovered. These data indicate that an Asp-Asp couple at this position in PBP 2 is requisite for decreasing penicillin susceptibility of *N. gonorrhoeae*.

Characterization of individual 345a and 346a insertion mutants of PBP 2

There are two potential explanations for the exclusive selection of an Asp-Asp couple: 1) insertions of other amino acids do not decrease the rate of acylation, and thus would not be selected by transformation of penicillin-susceptible recipient strains, or 2) insertion of amino acids other than aspartate decreases acylation, but also disrupts the essential TPase activity of PBP 2 and therefore cannot support growth. To distinguish between these two possibilities, we used site-directed mutagenesis to insert a variety of amino acids at positions 345a and 346a, purified the mutant proteins, and determined their rates of acylation with [¹⁴C]penicillin G. As shown in Table 1, nearly all of the insertions decreased the acylation rate with [¹⁴C]penicillin G (the lone exception being His346a, which slightly increased the acylation rate), with one insertion, Glu345a, having a greater effect on acylation than the Asp345a insertion. However, none of these individual *penA* mutants except Asp345a or Asp346a were capable of transforming FA19 to higher resistance, whereas transformants with decreased susceptibility to penicillin G were readily obtained using a *penA*-P551S/A516G double mutant, which has a k_2/K_S that is 2.9-fold lower than wild type (20). As described in Materials and Methods, transformants of *N. gonorrhoeae* could be readily selected using DNA encoding PBP 2 mutants with at least a threefold decrease in the k_2/K_S constant of penicillin compared to wild-type, provided that the mutant was a functional TPase.

Because the fold decreases in k_2/K_S values for PBP 2-H346a, -N345a and -Q345a mutants were below the threefold threshold for selection of transformants on penicillin (Table 1), we could not demonstrate unambiguously that these insertions were functional. Therefore, we took advantage of a *penA* allele (*penA35*) from the penicillin-resistant, cephalosporin-intermediate resistant strain 35/02, which confers a 100-fold increase in cefixime resistance to FA19 (31). The *penA35* allele contains 58 mutations compared to wild type *penA*, but does not have the Asp345a insertion (26); therefore, if the insertion disrupts TPase activity, no transformants containing the insertion should be recovered. The D345a, N345a, Q345a and H346a insertions were introduced into *penA35*, and the resulting clones were used to transform FA19 to increased cefixime resistance. Only the *penA35*-D345a construct resulted in the growth of resistant colonies, strongly suggesting that the insertion of histidine, asparagine, or glutamine at position 345a results in the loss of the essential TPase function. Taken together, these data are consistent with the conclusion that only an Asp insertion at position 345a or 346a is capable of both decreasing the rate of acylation of penicillin G and retaining TPase activity.

Role of Asp346 and Ser363 in TPase activity of PBP 2

The interaction of Asp346 and Ser363 shown in Fig. 1B suggests that insertion of Asp345a may impact enzyme activity by altering or disrupting the hydrogen bonds between Asp346 and Ser363, and therefore we employed a mutagenesis approach to investigate the roles of these residues in the activity of PBP 2. Asp346 and Ser363 were mutated individually to Ala, and each mutant PBP 2 variant was examined for its rate of acylation with penicillin G and its ability to support growth of *N. gonorrhoeae* (as a measure of its TPase activity). The acylation rates of PBP 2-D346A and PBP 2-S363A were both decreased around fivefold, about the same as PBP2-D345a or PBP 2-6140CT (20), compared to wild-type PBP 2 (Table 1). Despite the fivefold decrease in the k_2/K_S of penicillin G, neither *penA*-D346A nor *penA*-S363A was capable of transforming FA19 to decreased susceptibility (i.e. neither supported growth of *N. gonorrhoeae*), whereas hundreds of transformants were obtained with *penA* constructs encoding PBP 2-D345a or PBP2-6140CT. These data strongly suggest that although the D346A and S363A mutations decrease the rate of acylation with penicillin G, they also render the enzyme non-functional as a TPase, highlighting the importance of the interaction between these two amino acids for catalyzing TPase activity.

Structural comparison of *N. gonorrhoeae* PBP 2 with other Class B PBPs

Another well-studied Class B PBP whose structure is known, PBP 2x from *S. pneumoniae* (SpPBP 2x), also contains an SSN active-site motif (40). While these two PBPs share only 20% sequence identity, inspection of the crystal structure of SpPBP 2x revealed that Ser396 (the middle serine in the SSN motif) and Asp373 in the equivalent of the β 2a- β 2d loop in PBP 2x form a nearly identical set of interactions as Asp346 and Ser363 in NgPBP 2 (Fig. 2A,B). Indeed, superimposition of the two structures shows that there is almost complete overlap of the two residues (Fig. 1 Supplemental), suggesting a broad conservation of structure and function of this interaction, at least in PBPs harboring an SSN motif.

We recently reported the structure of the Class B-like PBP, PBPA from *M. tuberculosis* (MtPBPA) (41), which shows an unusual disulfide bond between a Cys residue in the X position of the SXN motif and a Cys residue in the equivalent of the β 2a- β 2d loop (Fig. 2C). The architecture of this covalent bond is very reminiscent of the Asp-Ser interaction in NgPBP 2 and SpPBP 2x. An additional Class B PBP whose structure is known, PBP 2a from methicillin-resistant *Staphylococcus aureus* (SaPBP 2a) (42), contains an SDN motif in which the Asp carboxylate forms an electrostatic interaction with an Arg residue in the loop equivalent to the β 2a- β 2d loop in NgPBP 2 (Fig. 2d). Thus, in four different Class B PBPs, an interaction between the middle residue of the SXN motif and a residue within the equivalent of the β 2a- β 2d loop is observed. These data prompted a bioinformatics analysis to determine the extent of this apparently conserved interaction in Class B PBPs from a wide range of bacterial genera and species.

Multiple sequence alignment of Class B PBPs

We identified the top 1000 sequences in a Blast search using NgPBP 2 as a query (see Methods for more details) and culled highly similar (>90%) sequences to decrease redundancy. Following multi-sequence alignment, three major groups (which we denote as Groups 1-3) of Class B PBPs were evident: Group 1 PBPs contained an SSN motif, Group 2 PBPs contained an SCN motif, and Group 3 PBPs contained an SDN motif. To identify as many group members as possible, BLAST searches for Group 2 and Group 3 PBPs were undertaken using MtPBPA and SaPBP 2a, respectively, as query sequences, and again redundant sequences from each of the three groups were culled by eliminating those with >90% sequence identity. The sequences in each group were then aligned using the multi-alignment program MUSCLE (36). Below, we summarize the major findings of these analyses.

SSN-containing PBPs (Group 1)—This is the largest group, with 364 PBPs included in the alignment (Supplemental Fig. 2). Strikingly, in 95% of the sequences, a conserved Asp residue is observed between 16 and 24 residues N-terminal to the SSN motif (Fig. 3). The remaining 5% contain either an asparagine or serine residue at this position of the alignment, both of which are hydrogen-bonding acceptors/donors that presumably could substitute for the aspartate in linking the β 2a- β 2d loop to the SSN motif. We also observed that nearly 10% of the PBPs (30/364) had alternative residues, e.g. aspartate, glutamine, and cysteine, at the third position of the SSN motif.

SCN-containing PBPs (Group 2)—This group comprised 135 sequences (Supplemental Fig. 3), which could be further divided into two subgroups (2a and 2b). Subgroup 2a sequences (110 members) contained a conserved cysteine 11-16 residues N-terminal to the SCN motif (Fig. 3 and Supplemental Fig. 3A), while in Subgroup 2b sequences (25 members), the conserved cysteine was located farther N-terminal to the motif (24-42 residues) (Fig. 3 and Supplemental Fig. 3B). None of the Subgroup 2a PBPs and only 20% of the Subgroup 2b PBPs harbored an additional cysteine residue in the region between the SXXX and SCN motifs, but, if present, none were conserved.

SDN-containing PBPs (Group 3)—Group 3 PBPs were the smallest group, with only 45 representatives (Fig. 3 and Supplemental Fig. 4). Thirty-four of these sequences (75%) contained a conserved arginine in the same relative position as in SaPBP 2a, while the remaining 11 (25%) contained a threonine residue at that position, which, as posited above, could substitute in the interaction of the loop with Asp463 in the SDN motif (this interaction would be the reverse of that in NgPBP 2 and SpPBP 2x). Taken together, it appears that an interaction between the X residue of the SXN motif and a residue within the equivalent of the β 2a- β 2d loop is highly conserved in Class B PBPs.

Analysis of NgPBP 2 with cysteine and aspartate substitutions at Ser363: To determine if either a cysteine or aspartate residue could substitute for Ser363 in the SXN motif of NgPBP 2, we incorporated these mutations into the protein and determined the k_2/K_S constants for [14 C]penicillin G (Table 1). Whereas the S363D mutation lowered the acylation rate of NgPBP 2 by 7-fold, the S363C mutation had only a minor effect on acylation (1.5-fold decrease). Transformation experiments to assess function revealed that neither of mutant genes was capable of transforming FA19 to higher resistance, whereas in the same experiment the *penA-D345a* gene generated hundreds of transformants. Because substitution of Ser363 with Asp would likely disrupt interaction with Asp346 from the β 2a- β 2d loop, we also mutated Asp346 in *penA-S363D* to Arg to mimic the interaction in SaPBP 2a, but while the acylation rate remained low, no transformants with reduced susceptibility could be obtained.

While these results strongly suggested that the S363D mutation abolishes the TPase activity of NgPBP 2, the inability to select transformants containing the S363C mutation could have been due to its minimal effects on acylation. Therefore, as described above, we incorporated the S363C mutation into the highly resistant *penA35* allele and transformed the *penA35-S363C* mutant into FA19. Transformants were selected for increased resistance to cefixime, and sequencing of the *penA* gene from these colonies confirmed the presence of the S363C mutation. Thus, cysteine is capable of substituting for Ser363 without compromising the TPase activity of NgPBP 2, presumably by preserving the interaction between the β 2a- β 2d loop and the SXN motif.

Flexibility of the β 2a- β 2d loop in PBP2-Asp345a insertion mutant

In SpPBP 2x from the cefotaxime-resistant strains 5204 and 328 (PBP 2x sequences from these strains are nearly identical), two mutations involved in decreasing the rate of acylation of cefotaxime, I371T and R384G, are located in the equivalent of the β 2a- β 2d loop of NgPBP 2. Interestingly, the structure of SpPBP 2x from strain 328 revealed disordering and displacement of approximately 30 residues encompassing the equivalent of the β 2a- β 2d loop up to the SSN motif of the active site (43), and increased susceptibility of this loop to proteolytic digestion of purified PBP 2x from strain 5204 provided corroborating evidence of this flexibility in solution (44). The flexibility of this loop has been posited to underlie the effects of the substitutions on the acylation rate and decreased MICs.

To examine whether the Asp345a insertion in NgPBP 2 increases flexibility of the β 2a- β 2d loop in a manner similar to the aforementioned mutations in SpPBP 2x, we carried out proteolytic susceptibility experiments for PBP 2 and PBP 2-Asp345a. As shown in Fig. 4A and 4B, these two proteins had identical sensitivities to trypsin in solution. The lack of trypsin sensitivity of PBP 2-D345a is not due to an absence of cleavage sites, as the β 2a- β 2d loop contains three potential trypsin sites, following Arg331, Lys338, and Arg345. We also examined whether mutation of either D346 or S363 to alanine, both of which abolish TPase activity (as indicated by failure to transform *N. gonorrhoeae*), disrupts the tethering of the β 2a- β 2d loop to the SSN motif, thereby inducing flexibility and increasing proteolytic sensitivity of the mutant enzymes. As shown in Fig. 4C and 4D, both mutations markedly increased proteolytic sensitivity of PBP 2 compared to the wild-type or Asp345a insertion mutant. These data show that loss of TPase function is likely due to an increased flexibility of the β 2a- β 2d loop and suggests that the Asp345a insertion acts by a specific mechanism to lower the rate of acylation and not by increasing flexibility of the β 2a- β 2d loop.

Discussion

Asp345a insertions are nearly ubiquitous in penicillin-resistant strains of *N. gonorrhoeae*, but the mechanism by which the Asp345a insertion lowers the acylation rate for penicillin while preserving TPase function is unknown. In the absence of structural information, we employed mutagenesis to address this question and identified an interaction between the middle residue of the SXN motif (Ser363 in NgPBP 2) and a residue in a loop that precedes the motif (Asp346 in NgPBP 2) that is both required for TPase activity and important (but not essential) for penicillin binding. Mutation of either of these residues mediating this interaction to Ala lowers the k_2/K_S acylation rate constant by about the same fold as an Asp345a insertion, but also renders PBP 2 inactive as a TPase (based on its inability to support growth). Bioinformatics analyses revealed that an interaction between the SXN motif and the loop above the active site is a highly conserved feature of all Class B PBPs. The implications of these findings for the transpeptidase function of PBPs, as well as resistance to β -lactams, are discussed below.

Because there is no *in vitro* assay to quantify TPase activity, we assessed the capacity of PBP 2 mutants to transform *N. gonorrhoeae* to decreased penicillin susceptibility as a measure of TPase function. As long as the mutation decreased the k_2/K_S of penicillin G threefold (a threshold at which resistant colonies could be readily obtained), transformation of FA19 to increased penicillin resistance was a straightforward and reliable method, because PBP 2 is essential and loss of TPase activity would not support bacterial growth. While this method is qualitative, it is clinically relevant, as those mutations that lower the TPase activity below the level that supports growth would never be observed in clinical isolates. Hence, the transformation assay is a useful and informative method to determine the affects of mutations on TPase activity of essential PBPs, especially in naturally competent organisms such as *N. gonorrhoeae*.

The observation that only an aspartate insertion at position 345a or 346a decreases the rate of penicillin binding of PBP 2 without compromising TPase activity, whereas insertions of other amino acids, including those that are similar to aspartate (e.g. glutamate or asparagine), disrupt TPase activity, is intriguing. These data indicate that only an Asp-Asp couple can lower k_2/K_S whilst also preserving TPase function. We also show that both PBP 2-D346A and PBP 2-S363A (neither of which catalyze TPase activity) are more susceptible to proteolysis compared to wild-type, suggesting that once the tether between the β -hairpin loop and the SXN motif is disrupted, the loop becomes more flexible. In contrast, the D345a insertion does not increase sensitivity to proteolysis, suggesting that the loop remains tethered. Hence, the Asp insertion lowers reactivity with penicillin in a very specific way, most likely through perturbation of the interaction of Asp346 in the β 2a- β 2d loop with Ser363 of the SSN motif. One possibility to explain the apparent requirement of an Asp-Asp couple is that one of the two aspartates is needed to retain the required interaction of the loop with Ser363, while the other aspartate alters that interaction in a subtle way that decreases the rate of acylation of penicillin G.

One of the most surprising outcomes of this study was the essentially absolute conservation of an interaction of a residue in the loop with the middle residue of the SXN motif in Class B PBPs that was independent of the physical nature of the interaction. When bioinformatics and structural data are considered together with our mutational and biochemical analyses of NgPBP 2, it is clear that all Class B PBPs have a crucial and highly conserved connection between the β -hairpin loop above the active site and the X residue in the SXN motif (Fig 3), suggesting that this connection is necessary for TPase activity of the PBP.

Inspection of the crystal structures of three bifunctional Class A PBPs, PBPs 1a and 1b from *S. pneumoniae* and PBP 2 from *S. aureus*, suggests that a similar connection also exists in other HMM PBPs. SpPBP 1a contains an SRN motif, and the arginine (Arg429) of the motif interacts with Asp412, which is located on the equivalent of the β 2a- β 2d hairpin extension loop that precedes the SRN motif (Fig. 5A) (45). SpPBP 1b harbors a tryptophan (W517) in the middle position of the SXN motif, and this aromatic amino acid forms two interactions with residues in the loop: 1) a π - π interaction with the phenolic side chain of Tyr498, and 2) a carboxamide- π interaction with Asn485 (Fig. 5B) (46, 47). Lastly, SaPBP 2 has an SFN motif where Phe455 forms a π - π interaction with the loop residue His442, which is held in place by interactions of the imidazolium nitrogens with two neighboring aspartate residues (Fig. 5C) (48). Although a comprehensive analysis has not been carried out, it appears that Class A PBPs also contain a conserved interaction between the loop that resides above the active site and the middle residue of the SXN motif.

The results from this study are highly reminiscent of those with *E. coli* PBP 5, a LMM PBP/D-Ala carboxypeptidase (CPase) with a relatively high β -lactamase activity ($t_{1/2}$ of the penicilloyl-enzyme complex \approx 10 min) (49). This PBP contains a loop (referred to as the 74-90 loop) that precedes the SXN motif (S¹¹⁰GN¹¹² in EcPBP 5) in a similar position in the primary sequence as the β 2a- β 2d hairpin extension loop in NgPBP 2. Two consecutive Ser residues on this loop (Ser86 and Ser87) interact with side chain and main chain atoms of residues within or adjacent to the SGN motif (Fig. 5D) (50). Although these interactions are fundamentally different than those discussed above for Class B PBPs, there is still a strong similarity in that the 74-90 loop of PBP 5 connects to the SGN motif through hydrogen-bonding interactions.

We have studied a PBP 5 point mutant (PBP 5-G105D; also called PBP 5), which has a 5-fold decrease in acylation rate (relative to wild-type) with penicillin G, but is deficient in CPase activity (49, 51). The crystal structure of PBP 5 revealed that while all of the active site motifs were intact, the 74-90 loop was disordered, suggesting that an ordered loop is

essential for carboxypeptidase activity but not β -lactam binding (52). Subsequent biochemical and mutational experiments, in which the 74-90 loop was deleted in the wild-type background or the two Ser residues were mutated to Ala, showed that disordering of the loop was the primary reason for the loss of CPase activity and reduced penicillin binding in the mutant enzyme (50). Given the equivalence of the 74-90 loop to the β 2a- β 2d loop in NgPBP 2, these results are strikingly similar to our observations in the PBP 2-D346A and -S363A mutants (i.e. a decrease but not loss of penicillin-binding and loss of functional TPase/CPase activity).

These results all point to a critical role of the β 2a- β 2d loop (and its equivalents) in TPase/CPase activity of PBPs. One explanation for the importance of this interaction in TPase activity is that the loop may be critical for binding and orienting the natural peptide substrate; this view is supported by the crystal structure of *E. coli* PBP 6 in complex with a peptidoglycan fragment containing a pentapeptide in which there are hydrogen bonds between the equivalent loop and the L-Lys of the peptide (53). Alteration of the structure of the loop by insertions other than aspartate would likely prevent such interactions and therefore compromise TPase activity. By comparison, β -lactam antibiotics are much smaller and interactions with the β 2a- β 2d loop are less important for penicillin-binding activity; consequently, acylation by β -lactams is less affected by the Asp345a insertion.

Our study suggests that mutations or insertions into the loop preceding the SXN motif can be exploited for increasing resistance, provided that the PBPs remain functional TPases. Indeed, two other PBPs, SpPBP 2x and PBP5fm from penicillin-resistant strains of *S. pneumoniae* and *Enterococcus faecium* respectively, have acquired mutations or an insertion in the loop that have been shown to confer decreased susceptibility to β -lactam antibiotics. PBP5fm, a Group 3 PBP with an SDN motif and conserved arginine in the loop, harbors an insertion of a serine (Ser466') that, when present, increases the MIC of penicillin twofold (54, 55). In SpPBP 2x from strain 5204, reversion of two mutations in the loop, I371T and R384G, back to wild-type either individually or together and subsequent recombination back into *S. pneumoniae* resulted in a two- to threefold decrease in the MIC of cefotaxime (44). As mentioned above, I371T and R384G in *S. pneumoniae* strains 328 and 5204 increase flexibility of the equivalent of the β 2a- β 2d loop, as evidenced by increased proteolytic degradation of the enzyme and disordering of the loop in the crystal structure (43, 44). Our data with NgPBP 2, however, point to an entirely different and more specific mechanism because the Asp345a insertion does not increase the proteolytic susceptibility of the protein. Indeed, the increased proteolytic sensitivity of the non-functional PBP 2-D346A and -S363A mutants suggests that disruption of the loop-SXN motif interaction induces disorder in this loop and is responsible for loss of essential TPase activity.

In conclusion, insertion of an aspartate, but no other amino acid, in the β 2a- β 2d loop of NgPBP 2 at position 345a or 346a lowers the rate of acylation by penicillin G, whilst preserving essential TPase function. This, together with the requirement of an Asp-Asp couple and the absence of flexibility in the β 2a- β 2d resulting from the insertion, suggests a very precise mechanism underlying this mechanism of penicillin resistance involving perturbation but not disruption of an important interaction between the β 2a- β 2d loop and the SxN active site motif. The importance of this interaction is highlighted by its conservation in Class B and other PBPs. Overall, these findings hint at the delicate balancing act that occurs during the evolution of resistance, in which mutations lower the susceptibility of the target for one ligand (the antibiotic) without compromising the natural function of the enzyme with its peptide substrate.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by Grants AI36901 (to R.A.N.) and GM66861 (to C.D.) from the National Institutes of Health.

References

1. CDC. Sexually Transmitted Disease Surveillance, 2007. 2009.
2. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sex Transm Dis.* 1992; 19:61–77. [PubMed: 1595015]
3. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, Zimba D, Vernazza PL, Maida M, Fiscus SA, Eron JJ Jr. AIDSCAP Malawi Research Group. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. *Lancet.* 1997; 349:1868–1873. [PubMed: 9217758]
4. Golparian D, Hellmark B, Fredlund H, Unemo M. Emergence, spread and characteristics of *Neisseria gonorrhoeae* isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. *Sex Transm Infect.* 2010; 86:454–460. [PubMed: 20940159]
5. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama SI, Kitawaki J, Unemo M. Is *Neisseria gonorrhoeae* initiating a future era of untreatable gonorrhea? Detailed characterization of the first high-level ceftriaxone resistant strain. *Antimicrob Agents Chemother.* 2011; 55:3538–3545. [PubMed: 21576437]
6. Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, Watanabe H, Kitawaki J. Ceftriaxone-resistant *Neisseria gonorrhoeae*, Japan. *Emerg Infect Dis.* 2011; 17:148–149. [PubMed: 21192886]
7. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant *N. gonorrhoeae* in Europe (France): novel *penA* mosaic allele in a successful international clone causes treatment failure. *Antimicrob Agents Chemother.* 2011
8. Shafer, WM.; Folster, JP.; Nicholas, RA. Molecular Mechanisms of Antibiotic Resistance Expressed by the Pathogenic *Neisseria*. In: Genco, C.; Wetzler, L., editors. *Neisseria: Molecular Mechanisms of Pathogenesis*. Caister Academic Press; Norfolk, U.K: 2010. p. 245-270.
9. Cannon JG, Sparling PF. The genetics of the gonococcus. *Ann Rev Genet.* 1984; 38:111–133.
10. Sparling PF, Sarubbi FAJ, Blackman E. Inheritance of low-level resistance to penicillin, tetracycline, and chloramphenicol in *Neisseria gonorrhoeae*. *J Bacteriol.* 1975; 124:740–749. [PubMed: 810479]
11. Ito M, Deguchi T, Mizutani KS, Yasuda M, Yokoi S, Ito S, Takahashi Y, Ishihara S, Kawamura Y, Ezaki T. Emergence and spread of *Neisseria gonorrhoeae* clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. *Antimicrob Agents Chemother.* 2005; 49:137–143. [PubMed: 15616287]
12. Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. *FEMS Microbiol Rev.* 2008; 32:149–167. [PubMed: 18194336]
13. Vollmer W, Seligman SJ. Architecture of peptidoglycan: more data and more models. *Trends Microbiol.* 2010; 18:59–66. [PubMed: 20060721]
14. Tipper DJ, Strominger JL. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. *Proc Natl Acad Sci USA.* 1965; 54:1133–1141. [PubMed: 5219821]
15. Ghuysen JM. Serine β -lactamases and penicillin-binding proteins. *Annu. Rev. Microbiol.* 1991; 45:37–67. [PubMed: 1741619]
16. Goffin C, Ghuysen JM. Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. *Microbiol Mol Biol Rev.* 1998; 62:1079–1093. [PubMed: 9841666]

17. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. *FEMS Microbiol Rev.* 2008; 32:234–258. [PubMed: 18266856]
18. Job V, Carapito R, Vernet T, Dessen A, Zapun A. Common alterations in PBP1a from resistant *Streptococcus pneumoniae* decrease its reactivity toward β -lactams: structural insights. *JBiol Chem.* 2008; 283:4886–4894. [PubMed: 18055459]
19. Pernot L, Chesnel L, Le Gouellec A, Croize J, Vernet T, Dideberg O, Dessen A. A PBP2x from a clinical isolate of *Streptococcus pneumoniae* exhibits an alternative mechanism for reduction of susceptibility to β -lactam antibiotics. *J Biol Chem.* 2004; 279:16463–16470. [PubMed: 14734544]
20. Powell AJ, Tomberg J, Deacon AM, Nicholas RA, Davies C. Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of *Neisseria gonorrhoeae* reveal an unexpectedly subtle mechanism for antibiotic resistance. *J Biol Chem.* 2009; 284:1202–1212. [PubMed: 18986991]
21. Tomberg J, Unemo M, Davies C, Nicholas RA. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in *Neisseria gonorrhoeae*: role of epistatic mutations. *Biochemistry.* 2010; 49:8062–8070. [PubMed: 20704258]
22. Chesnel L, Pernot L, Lemaire D, Champelovier D, Croize J, Dideberg O, Vernet T, Zapun A. The structural modifications induced by the M339F substitution in PBP2x from *Streptococcus pneumoniae* further decreases the susceptibility to β -lactams of resistant strains. *J Biol Chem.* 2003; 278:44448–44456. [PubMed: 12923202]
23. Spratt BG. Hybrid penicillin-binding proteins in penicillin-resistant strains of *Neisseria gonorrhoeae*. *Nature.* 1988; 332:173–176. [PubMed: 3126399]
24. Maness MJ, Sparling PF. Multiple antibiotic resistance due to a single mutation in *Neisseria gonorrhoeae*. *J Infect Dis.* 1973; 128:321–330. [PubMed: 4269625]
25. Kellogg DS, Peacock WL, Deacon WE, Browh L, Perkle CI. *Neisseria gonorrhoeae*. I. Virulence genetically linked to colonial variation. *J Bacteriol.* 1963; 85:1274–1279. [PubMed: 14047217]
26. Lindberg R, Fredlund H, Nicholas RA, Unemo M. *Neisseria gonorrhoeae* isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in *penA*, *mtrR*, *porB1b*, and *ponA*. *Antimicrob Agents Chemother.* 2007; 51:2117–2122. [PubMed: 17420216]
27. Elkins C, Thomas CE, Seifert HS, Sparling PF. Species-specific uptake of DNA by gonococci is mediated by a 10-base-pair sequence. *J Bacteriol.* 1991; 173:3911–3913. [PubMed: 1904861]
28. Powell AJ, Liu ZJ, Nicholas RA, Davies C. Crystal structures of the lytic transglycosylase MltA from *N. gonorrhoeae* and *E. coli*: insights into interdomain movements and substrate binding. *J Mol Biol.* 2006; 359:122–136. [PubMed: 16618494]
29. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene.* 1989; 77:51–59. [PubMed: 2744487]
30. Barbour AG. Properties of penicillin-binding proteins in *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother.* 1981; 19(2):316–322. [PubMed: 6812490]
31. Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother.* 2009; 53:3744–3751. [PubMed: 19528266]
32. Ropp PA, Hu M, Olesky M, Nicholas RA. Mutations in *ponA*, the gene encoding penicillin-binding protein 1, and a novel locus, *penC*, are required for high-level chromosomally mediated penicillin resistance in *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother.* 2002; 46:769–777. [PubMed: 11850260]
33. Frere, JM.; Nguyen-Disteche, M.; Coyette, J.; Joris, B. The chemistry of β -lactams. Chapman & Hall; Glasgow: 1992. Mode of action: Interaction with the penicillin binding proteins; p. 148–196.
34. Stefanova ME, Tomberg J, Olesky M, Holtje JV, Gutheil WG, Nicholas RA. *Neisseria gonorrhoeae* penicillin-binding protein 3 exhibits exceptionally high carboxypeptidase and β -lactam binding activities. *Biochemistry.* 2003; 42:14614–14625. [PubMed: 14661974]
35. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 1997; 25:3389–3402. [PubMed: 9254694]

36. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* 2004; 32:1792–1797. [PubMed: 15034147]
37. Schneider TD, Stephens RM. Sequence logos: a new way to display consensus sequences. *Nucleic Acids Res.* 1990; 18:6097–6100. [PubMed: 2172928]
38. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. *Genome Res.* 2004; 14:1188–1190. [PubMed: 15173120]
39. Brannigan JA, Tirodimos IA, Zhang Q-Y, Dowson CG, Spratt BG. Insertion of an extra amino acid is the main cause of the low affinity of penicillin-binding protein 2 in penicillin-resistant strains of *Neisseria gonorrhoeae*. *Mol Microbiol.* 1990; 4(6):913–919. [PubMed: 2120542]
40. Gordon E, Mouz N, Duee E, Dideberg O. The crystal structure of the penicillin-binding protein 2x from *Streptococcus pneumoniae* and its acyl-enzyme form: implication in drug resistance. *J Mol Biol.* 2000; 299:477–485. [PubMed: 10860753]
41. Fedarovich A, Nicholas RA, Davies C. Unusual conformation of the SxN motif in the crystal structure of penicillin-binding protein A from *Mycobacterium tuberculosis*. *J Mol Biol.* 2010; 398:54–65. [PubMed: 20206184]
42. Lim D, Strynadka NC. Structural basis for the β -lactam resistance of PBP2a from methicillin-resistant *Staphylococcus aureus*. *Nat Struct Biol.* 2002; 9:870–876. [PubMed: 12389036]
43. Dessen A, Mouz N, Gordon E, Hopkins J, Dideberg O. Crystal structure of PBP2x from a highly penicillin-resistant *Streptococcus pneumoniae* clinical isolate: a mosaic framework containing 83 mutations. *J Biol Chem.* 2001; 276:45106–45112. [PubMed: 11553637]
44. Carapito R, Chesnel L, Vernet T, Zapun A. Pneumococcal β -lactam resistance due to a conformational change in penicillin-binding protein 2x. *J Biol Chem.* 2006; 281:1771–1777. [PubMed: 16303769]
45. Contreras-Martel C, Job V, Di Guilmi AM, Vernet T, Dideberg O, Dessen A. Crystal structure of penicillin-binding protein 1a (PBP1a) reveals a mutational hotspot implicated in β -lactam resistance in *Streptococcus pneumoniae*. *J Mol Biol.* 2006; 355:684–696. [PubMed: 16316661]
46. Lovering AL, De Castro L, Lim D, Strynadka NC. Structural analysis of an “open” form of PBP1B from *Streptococcus pneumoniae*. *Protein Sci.* 2006; 15:1701–1709. [PubMed: 16751607]
47. Macheboeuf P, Di Guilmi AM, Job V, Vernet T, Dideberg O, Dessen A. Active site restructuring regulates ligand recognition in class A penicillin-binding proteins. *Proc Natl Acad Sci U S A.* 2005; 102:577–582. [PubMed: 15637155]
48. Lovering AL, de Castro LH, Lim D, Strynadka NC. Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. *Science.* 2007; 315:1402–1405. [PubMed: 17347437]
49. Nicholas RA, Strominger JL. Site-directed mutants of a soluble form of penicillin-binding protein 5 from *Escherichia coli* and their catalytic properties. *J Biol Chem.* 1988; 263:2034–2040. [PubMed: 3276680]
50. Nicholas RA, Krings S, Tomberg J, Nicola G, Davies C. Crystal structure of wild-type penicillin-binding protein 5 from *Escherichia coli*: implications for deacylation of the acyl-enzyme complex. *J Biol Chem.* 2003; 278:52826–52833. [PubMed: 14555648]
51. Amanuma H, Strominger JL. Purification and properties of penicillin-binding proteins 5 and 6 from the *dacA* mutant strain of *Escherichia coli* (JE 11191). *J Biol Chem.* 1984; 259:1294–1298. [PubMed: 6363404]
52. Davies C, White SW, Nicholas RA. Crystal structure of a deacylation-defective mutant of penicillin-binding protein 5 at 2.3-Å resolution. *J Biol Chem.* 2001; 276:616–623. [PubMed: 10967102]
53. Chen Y, Zhang W, Shi Q, Heseck D, Lee M, Mobashery S, Shoichet BK. Crystal structures of penicillin-binding protein 6 from *Escherichia coli*. *J Am Chem Soc.* 2009; 131:14345–14354. [PubMed: 19807181]
54. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L. Penicillin-binding protein 5 sequence alterations in clinical isolates of *Enterococcus faecium* with different levels of β -lactam resistance. *J Infect Dis.* 1998; 178:159–163. [PubMed: 9652435]
55. Sauvage E, Kerff F, Fonce E, Herman R, Schoot B, Marquette JP, Taburet Y, Prevost D, Dumas J, Leonard G, Stefanic P, Coyette J, Charlier P. The 2.4-Å crystal structure of the penicillin-resistant

penicillin-binding protein PBP5fm from *Enterococcus faecium* in complex with benzylpenicillin. *Cell Mol Life Sci.* 2002; 59:1223–1232. [PubMed: 12222968]




Fig. 1. Interaction of Asp346 in the β -hairpin extension of NgPBP 2 with the middle Ser in the SSN active-site motif

A, the structure of NgPBP 2, with the β -hairpin extension (also referred to as the β 2a- β 2d loop) shown in green. The side chains of the residues within the three active site motifs are shown as orange bonds, and the backbone of the SxN motif is colored red. The active site, N- and C-termini, and the penicillin-binding/TPase and N-terminal domains are highlighted. *B*, a closer view of the active site, showing hydrogen-bonding interactions between residues in the interaction of Asp346 in the β 2a- β 2d loop with Ser363 of the SSN motif. Putative hydrogen bonds are shown as dashed lines and structural elements are labeled.




Fig. 2. Conservation of the interaction between the X residue of the SXN motif with a residue in the preceding loop in several Class B PBPs

A, PBP 2 from *N. gonorrhoeae* (PDB code 3EQU; (20)), showing the interaction between Asp346 and Ser363. Structural elements and the SXN motif are as shown; B, PBP 2x from *S. pneumoniae* (1QME; (40)), showing the interaction between Asp373 and Ser396; C, *M. tuberculosis* PBPA (3LO7; (41)), showing a disulfide bond between Cys266 and Cys282; and D, PBP 2a from methicillin-resistant *S. aureus* (1VQQ; (42)), showing the interaction between Arg445 and Asp463. Hydrogen bonds are depicted by the dotted lines, and the numbers next to the lines refer to the lengths of the bonds in Å. The orientation of the PBPs in A-D is the same as in Fig. 1B.




Fig. 3. Conservation of an amino acid in the β 2a- β 2d loop that interacts with the X residue in the SXN motif in each of the three groups of PBPs

The conservation of a residue in the loop preceding the SXN motif and the X residue of that motif in each PBP Group as shown by a WebLogo plot (37, 38) of multiple-sequence alignments. The connected arrows in each plot point to the two interacting residues in each group of PBPs. See text for details.




Fig. 4. Trypsin sensitivity of wild-type and mutant PBP 2 variants

PBP 2 variants (83 μ g) were incubated with 50 ng trypsin in 20 mM Tris, pH 8.0, 500 mM NaCl, and 10% glycerol at room temperature. At the indicated times, samples were withdrawn, added to SDS-PAGE loading buffer, and separated on a 10% gel. The gels were stained with Coomassie Brilliant Blue R-250. The molecular weights of protein standards are indicated on the side of the first gel.




Fig. 5. The interaction between amino acids in the SXN motif and within the β -hairpin loop is conserved in other non-Class B PBPs
 A, PBP 1a from *S. pneumoniae* (PDB code 2C6W; (45)), a bifunctional Class A PBP; B, PBP 1b from *S. pneumoniae* (2FFF; (46, 47)), a Class A PBP; C, PBP 2 from *S. aureus* (2OLU; (48)), a Class A PBP; and D, PBP 5, a LMM CPase from *E. coli* (1NZO; (50)). Hydrogen bonds are shown as dashed lines. The orientation of the PBPs in A-D is the same as in Fig. 1B and 2.

Table 1
Kinetic constants of PBP 2 mutants

The k_2/K_s constants of [^{14}C]penicillin G for the indicated PBP 2 variants were determined using purified protein as described in Materials and Methods. Insertions are denoted by a small a following the amino acid, whereas mutations are denoted in capitals (e.g. PBP 2-D346a is an insertion after amino acid 346, while PBP 2-D346A is a mutation of D346 to alanine).

PBP 2 Variants	k_2/K_s ($M^{-1}s^{-1}$)	Fold Change ^a	TPase activity ^b
PBP 2 WT	74,700 ± 5,000 (n=8)	---	+
PBP 2-D345aorD346a	12,200 ± 2,400 (n=16)	6.1	+
PBP 2-P551S/A516G	25,900 ± 2,400 (n=8)	2.9	+
PBP 2-E345a	19,900 ± 900 (n=4)	3.8	—
PBP 2-N345a	31,200 ± 1,800 (n=4)	2.4	-
PBP 2-Q345a	45,400 ± 1,400 (n=4)	1.6	-
PBP 2-A345 a	19,100 ± 900 (n=4)	3.9	-
PBP 2-E346a	5,100 ± 400 (n=4)	14.6	-
PBP 2-N346a	11,800 ± 100 (n=5)	6.3	-
PBP 2-Q346a	20,700 ± 1,400 (n=4)	3.6	-
PBP 2-K346a	16,300 ± 1,200 (n=4)	4.6	-
PBP 2-H346a	114,500 ± 6,300 (n=5)	0.7	-
PBP 2-D346A	14,600 ± 800 (n=8)	5.1	-
PBP 2-S363A	16,400 ± 3,800 (n=8)	4.6	-
PBP 2-S363C	51,300 ± 2,100 (n=8)	1.5	+
PBP 2-S363D	10,400 ± 2,300 (n=8)	7.2	-

^aFold change in k_2/K_s relative to PBP 2 WT.

^bTPase activity is defined as the capacity of the PBP 2 variant to support cell growth (see Methods for details).